Literature DB >> 27538023

Target validation: Switching domains.

Alessio Ciulli1.   

Abstract

Year:  2016        PMID： 27538023     DOI： 10.1038/nchembio.2154

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  10 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

Review 2.  Cancer epigenetics: from mechanism to therapy.

Authors:  Mark A Dawson; Tony Kouzarides
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

Review 3.  PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.

Authors:  Cigall Kadoch; Robert A Copeland; Heike Keilhack
Journal:  Biochemistry       Date:  2016-02-17       Impact factor: 3.162

4.  Target validation using chemical probes.

Authors:  Mark E Bunnage; Eugene L Piatnitski Chekler; Lyn H Jones
Journal:  Nat Chem Biol       Date:  2013-04       Impact factor: 15.040

5.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Authors:  Thomas A Paul; Parantu K Shah; Bhavatarini Vangamudi; Maria Kost-Alimova; Lisa Nottebaum; Xi Shi; Yanai Zhan; Elisabetta Leo; Harshad S Mahadeshwar; Alexei Protopopov; Andrew Futreal; Trang N Tieu; Mike Peoples; Timothy P Heffernan; Joseph R Marszalek; Carlo Toniatti; Alessia Petrocchi; Dominique Verhelle; Dafydd R Owen; Giulio Draetta; Philip Jones; Wylie S Palmer; Shikhar Sharma; Jannik N Andersen
Journal:  Cancer Res       Date:  2015-07-02       Impact factor: 12.701

6.  Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.

Authors:  Matthias G J Baud; Enrique Lin-Shiao; Teresa Cardote; Cynthia Tallant; Annica Pschibul; Kwok-Ho Chan; Michael Zengerle; Jordi R Garcia; Terence T-L Kwan; Fleur M Ferguson; Alessio Ciulli
Journal:  Science       Date:  2014-10-16       Impact factor: 47.728

7.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains.

Authors:  Junwei Shi; Eric Wang; Joseph P Milazzo; Zihua Wang; Justin B Kinney; Christopher R Vakoc
Journal:  Nat Biotechnol       Date:  2015-05-11       Impact factor: 54.908

8.  Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.

Authors:  Laetitia J Martin; Manfred Koegl; Gerd Bader; Xiao-Ling Cockcroft; Oleg Fedorov; Dennis Fiegen; Thomas Gerstberger; Marco H Hofmann; Anja F Hohmann; Dirk Kessler; Stefan Knapp; Petr Knesl; Stefan Kornigg; Susanne Müller; Herbert Nar; Catherine Rogers; Klaus Rumpel; Otmar Schaaf; Steffen Steurer; Cynthia Tallant; Christopher R Vakoc; Markus Zeeb; Andreas Zoephel; Mark Pearson; Guido Boehmelt; Darryl McConnell
Journal:  J Med Chem       Date:  2016-03-10       Impact factor: 7.446

Review 9.  Chemical genetics approaches for selective intervention in epigenetics.

Authors:  Andrew C Runcie; Kwok-Ho Chan; Michael Zengerle; Alessio Ciulli
Journal:  Curr Opin Chem Biol       Date:  2016-07-14       Impact factor: 8.822

10.  Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.

Authors:  Anja F Hohmann; Laetitia J Martin; Jessica L Minder; Jae-Seok Roe; Junwei Shi; Steffen Steurer; Gerd Bader; Darryl McConnell; Mark Pearson; Thomas Gerstberger; Teresa Gottschamel; Diane Thompson; Yutaka Suzuki; Manfred Koegl; Christopher R Vakoc
Journal:  Nat Chem Biol       Date:  2016-07-04       Impact factor: 15.040
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.